Literature DB >> 26057711

Against the clock towards new Ebola virus therapies.

Carles Martínez-Romero1, Adolfo García-Sastre2.   

Abstract

Since the end of 2013, West Africa has been suffering the largest Ebola virus (EBOV) outbreak in recorded history. The lack of health care infrastructure in the affected countries, as well as a concentration of infected cases in the most populated areas allowed the virus to spread with no control during the first months of the outbreak. With no specific treatment available to combat EBOV infection and its associated disease, an extraordinary worldwide effort was made to confront the severity of the situation and to establish new therapeutic strategies that would lead to better and faster control and eradicate the outbreak. In the last two years, several candidate therapies and potential vaccines against EBOV have arisen and human clinical trials are ongoing, in hopes of starting their deployment in the affected countries. This article reviews the current candidate therapies against EBOV, their stage of development and future prospects in battling EBOV outbreaks.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antivirals; Drug repurposing; Ebolavirus; Outbreak; Therapies; Virus-like particle

Mesh:

Substances:

Year:  2015        PMID: 26057711     DOI: 10.1016/j.virusres.2015.05.025

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  5 in total

1.  Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus.

Authors:  Yu Cong; Julie Dyall; Brit J Hart; Lisa Evans DeWald; Joshua C Johnson; Elena Postnikova; Huanying Zhou; Robin Gross; Oscar Rojas; Isis Alexander; Nicole Josleyn; Tengfei Zhang; Julia Michelotti; Krisztina Janosko; Pamela J Glass; Mike Flint; Laura K McMullan; Christina F Spiropoulou; Tim Mierzwa; Rajarshi Guha; Paul Shinn; Sam Michael; Carleen Klumpp-Thomas; Crystal McKnight; Craig Thomas; Ann E Eakin; Kathleen G O'Loughlin; Carol E Green; Paul Catz; Jon C Mirsalis; Anna N Honko; Gene G Olinger; Richard S Bennett; Michael R Holbrook; Lisa E Hensley; Peter B Jahrling
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

2.  Minimal In Vivo Efficacy of Iminosugars in a Lethal Ebola Virus Guinea Pig Model.

Authors:  Joanna L Miller; Simon G Spiro; Stuart D Dowall; Irene Taylor; Antony Rule; Dominic S Alonzi; Andrew C Sayce; Edward Wright; Emma M Bentley; Ruth Thom; Graham Hall; Raymond A Dwek; Roger Hewson; Nicole Zitzmann
Journal:  PLoS One       Date:  2016-11-23       Impact factor: 3.240

3.  The Ebola virus VP35 protein binds viral immunostimulatory and host RNAs identified through deep sequencing.

Authors:  Kari A Dilley; Alexander A Voorhies; Priya Luthra; Vinita Puri; Timothy B Stockwell; Hernan Lorenzi; Christopher F Basler; Reed S Shabman
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

4.  Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections.

Authors:  José A Marrugal-Lorenzo; Ana Serna-Gallego; Judith Berastegui-Cabrera; Jerónimo Pachón; Javier Sánchez-Céspedes
Journal:  Sci Rep       Date:  2019-01-09       Impact factor: 4.379

5.  Machine learning models identify molecules active against the Ebola virus in vitro.

Authors:  Sean Ekins; Joel S Freundlich; Alex M Clark; Manu Anantpadma; Robert A Davey; Peter Madrid
Journal:  F1000Res       Date:  2015-10-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.